Jean-Sebastien Garrigue
Santen SAS
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jean-Sebastien Garrigue as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:18 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT04133311 · A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan® in Patients With Open-Angle Glaucoma or Ocular HypertensionSanten SAS · completed · Open-Angle Glaucoma or Ocular Hypertension, Ocular Surface Disease · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:18 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:18 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial.Eur J Ophthalmol · 2016145 citationsRCR 8.4
- A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye.Eur J Ophthalmol · 201781 citationsRCR 5.5
- One-Year Efficacy and Safety of 0.1% Cyclosporine a Cationic Emulsion in the Treatment of Severe Dry Eye Disease.Eur J Ophthalmol · 201770 citationsRCR 4.9
- Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies.Br J Ophthalmol · 201951 citationsRCR 4.4
- Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease - a randomised comparative study.J Fr Ophtalmol · 201441 citationsRCR 2.4
- Efficacy and safety of a cationic emulsion in the treatment of moderate to severe dry eye disease: a randomized controlled study.Eur J Ophthalmol · 201637 citationsRCR 2.5
- A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.Br J Cancer · 200635 citationsRCR 1.1
- 21 citationsRCR 1.7
- Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study.J Ocul Pharmacol Ther · 20244 citationsRCR 1.3